tert-butyldiphenyl(thiophen-3-ylmethoxy)silane | 125849-86-7

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 英文名称: tert-butyldiphenyl(thiophen-3-ylmethoxy)silane
• 英文别名: tert-butyl(diphenyl)(3-thienylmethoxy)silane；3-(t-butyldiphenylsilyloxymethyl)tiophene；tert-butyl-diphenyl-(thiophen-3-ylmethoxy)silane
• CAS: 125849-86-7
• 化学式: C₂₁H₂₄OSSi
• 分子量: 352.572
• InChiKey: XHTAPTUZXDPIRM-UHFFFAOYSA-N

物化性质

• 沸点：
  415.0±37.0 °C(Predicted)
• 密度：
  1.08±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.82
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  37.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  tert-butyldiphenyl(thiophen-3-ylmethoxy)silane 在 正丁基锂 、 叔丁基锂 作用下， 以 四氢呋喃 、 乙醚 、 正己烷 、 正戊烷 为溶剂， 反应 22.33h， 生成
  参考文献：
  名称：

  Organic sensitizers bearing a trialkylsilyl ether group for liquid dye sensitized solar cells

  摘要：

  In this work we present the synthesis, optical characterization and performance of five metal-free sensitizers for dye-sensitized solar cells (DSSC). All dyes include, for the first time, a trialkylsilyl ether group in the pi-conjugated bridge (a thiophene ring). The influence of different donor unities, like triarylamine (TPA), 4H-pyranylidene and dithiafulvene has been evaluated in DSSC with a liquid I-3/I- electrolyte, obtaining the best results with the 4H-pyranylidene moiety. The size and the position of the bulky group have a great importance in the efficiency of the final devices.In order to explain the recombination processes and electron life-time, charge extraction (CE) and transient photovoltage (TPV) experiments have been carried out. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.dyepig.2015.07.026
• 作为产物：
  描述：

  [2-(tert-Butyl-diphenyl-silanyl)-thiophen-3-yl]-methanol 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以88%的产率得到tert-butyldiphenyl(thiophen-3-ylmethoxy)silane
  参考文献：
  名称：

  Regioselective Preparation of 2,4-, 3,4-, and 2,3,4-Substituted Furan Rings. 1. [1,4] O → C and [1,4] C → O Silyl Migrations of Silyl Ethers and Esters Attached to Furan and Thiophene Rings

  摘要：

  [1,4] O --> C and [1,4] C --> O rearrangements are described for a variety of furans and thiophenes. Treatment of 3-((silyloxy)methyl)furans and -thiophenes with n-BuLi in HMPA provided 2-silylated-3-(hydroxymethyl)furans and -thiophenes in good to excellent yields. The reaction was shown by crossover studies to proceed via an intramolecular [1,4] O --> C silyl migration. Silyl esters of 3-furoic acids also underwent an intramolecular [1,4] O --> C silyl migration to provide 2-silylated-3-furoic acids in moderate to good yield when treated with a mixture of LDA and HMPA. Finally, the above silyl migrations were shown to be reversible. Treatment of 2-silylated-3-(hydroxymethyl)furans and -thiophenes with NaH in DMF provided 3-((silyloxy)methyl)furans and -thiophenes in excellent yields via a [1,4] C --> O silyl migration. The [1,4] C --> O silyl migration was also shown to be an intramolecular process by a crossover study.

  DOI：

  10.1021/jo971097j

文献信息

• [EN] QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS<br/>[FR] DÉRIVÉS DE QUINAZOLINONE ET UTILISATION DE CES DÉRIVÉS EN TANT QU'INHIBITEURS DU B-RAF
  申请人：ASTRAZENECA AB

  公开号：WO2006024834A1

  公开（公告）日：2006-03-09

  The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

  该发明涉及化学式(I)的化合物或其药学上可接受的盐，具有B Raf抑制活性，因此在抗癌活性方面有用，并且在治疗人体或动物体的方法中有用。该发明还涉及制备所述化学化合物的方法，含有它们的药物组合物以及它们在制造用于在温血动物（如人类）中产生抗癌效果的药物中的使用。
• [EN] SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS<br/>[FR] QUINAZOLONES SUBSTITUES EN TANT QU'AGENTS ANTICANCEREUX
  申请人：ASTRAZENECA AB

  公开号：WO2005123696A1

  公开（公告）日：2005-12-29

  The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

  该发明涉及化学式（I）的化合物或其药学上可接受的盐，具有B Raf抑制活性，因此在抗癌活性方面具有用途，并因此在治疗人体或动物体的方法中有用。该发明还涉及制备所述化学化合物的方法，含有它们的药物组合物以及它们在制造用于在温血动物（如人）中产生抗癌效果的药物中的使用。
• [EN] QUINOXALINES AS B RAF INHIBITORS<br/>[FR] QUINOXALINES EN TANT QU'INHIBITEURS B-RAF
  申请人：ASTRAZENECA AB

  公开号：WO2006040568A1

  公开（公告）日：2006-04-20

  The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

  该发明涉及化学式(I)的化合物或其药学上可接受的盐，具有B Raf抑制活性，因此对其抗癌活性有用，从而在治疗人体或动物体的方法中使用。该发明还涉及制备所述化学化合物的方法，含有它们的药物组合物以及它们在制造用于在温血动物（如人类）中产生抗癌效果的药物的生产中的使用。
• Heterocycles useful in the treatment of benign prostatic hyperplasia
  申请人：Ortho-McNeil Pharmaceutical, Inc.

  公开号：US06384035B1

  公开（公告）日：2002-05-07

  This invention relates a to a series of heterocyclic substituted piperazines of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the &agr;-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this disease.

  这项发明涉及一系列异环取代哌嗪的化合物I的制药组合物，以及用于其制备的中间体。该发明的化合物选择性地抑制与α-1a肾上腺能受体的结合，该受体已被认为与良性前列腺增生有关。因此，这些化合物在治疗这种疾病方面具有潜在的用途。
• Quinoxalines as B Baf Inhhibitors
  申请人：Aquila Brian

  公开号：US20080207616A1

  公开（公告）日：2008-08-28

  The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

  本发明涉及公式(I)的化合物或其药学上可接受的盐，其具有B Raf抑制活性，并因此在其抗癌活性方面有用，因此可以用于人类或动物体的治疗方法。本发明还涉及制造所述化合物的工艺，含有它们的制药组合物以及它们在制造用于在温血动物（如人）中产生抗癌效果的药物的生产中的使用。